featured
Nivolumab + Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-Naïve Metastatic ccRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Urology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab Plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-Naïve Metastatic Clear-Cell Renal Cell Carcinoma
Eur Urol 2020 Dec 20;[EPub Ahead of Print], J Bedke, L Albiges, U Capitanio, RH Giles, M Hora, TB Lam, B Ljungberg, L Marconi, T Klatte, A Volpe, Y Abu-Ghanem, S Dabestani, SF Pello, F Hofmann, T Kuusk, R Tahbaz, T Powles, A BexFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.